Global pharmaceutical company Lupin Limited announced it has completed the acquisition of VISUfarma B.V., a European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners. The transaction marks a strategic move to expand Lupin’s specialty care portfolio and strengthen its presence across key European markets.
With the integration of VISUfarma, Lupin’s ophthalmology portfolio now exceeds 60 branded products, covering areas such as dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma brings a strong commercial footprint across Italy, the United Kingdom, Spain, Germany, and France, along with an experienced team and established relationships in the ophthalmology sector.
The acquisition is expected to enhance Lupin’s ability to address rising global demand for eye care solutions, driven by aging populations and increasing rates of diabetes-related eye conditions. VISUfarma reported approximately €53 million in revenue in 2025 and has been owned by GHO Capital since 2016.
Lupin, headquartered in Mumbai, operates in over 100 markets and focuses on branded and generic pharmaceuticals, complex generics, biotechnology products, and active pharmaceutical ingredients. The company maintains a strong presence in both India and the United States across multiple therapeutic areas, including respiratory, cardiovascular, and anti-diabetic treatments.
KEY QUOTES:
“The VISUfarma acquisition marks a very exciting milestone for Lupin, adding a differentiated portfolio of more than 60 innovative eye health products supported by an established commercial infrastructure. Beyond being immediately accretive, this strategic acquisition will also expand our presence across Europe and accelerate the build-out of our specialty franchise.”
Vinita Gupta, CEO, Lupin Limited
“We are thrilled to embark on this next chapter with Lupin. Their global expertise, vision, and commitment to ophthalmology make them the ideal partner to take VISUfarma to the next level. Together, we are confident that we can make a significant impact in advancing eye care across Europe and beyond.”
Paolo Cioccetti, CEO Italy, VISUfarma
